https://www.selleckchem.com/ph....armacological_epigen
hrombocytopenia. Although survival data in patients with ECOG PS 2 were notably inferior to the other cohorts, our findings are consistent with those previously reported in the population-specific studies of the ABOUND trials and lend additional support for the use of -paclitaxel-based regimens in historically understudied and vulnerable populations. Although survival data in patients with ECOG PS 2 were notably inferior to the other cohorts, our findings are consistent with those previously reported in the population-specifi
Like
Comment
Share
